Supriya Lifescience FY24 PAT up 32%

The Profit After Tax (PAT) for Q4 FY24 at Rs 36.40 crore, compared to Rs 38.23 crore in Q4 FY23

Merck Specialities’ unique initiative to raise bladder cancer awareness

Cupid receives vendor approval from Godrej Consumer for Supply of Kamasutra condoms

This significant achievement includes an initial order from GCPL valued at a substantial Rs. 2.4 crore

AbbVie receives positive CHMP opinion for Risankizumab for treatment ulcerative colitis

Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine

BlueRock Therapeutics receives FDA RMAT designation for Parkinson’s disease cell therapy candidate bemdaneprocel

Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s disease

Hyperfine bringing Swoop to India through distribution partnership with Radiosurgery Global

Strategic focus on India aims to make the Swoop® portable MR brain imaging system commercially available in a vast and underserved MRI market

Valent BioSciences opens new addition at Melnik and Shafer Biorational Research Center

Greg was also central to the planning, design, and construction of this facility

Merck to acquire EyeBio for US$ 1.3 billion upfront payment

Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration

AstraZeneca India posts FY 2023-24 revenue higher at Rs. 1,330 Cr

Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction

Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression